Vasa Denticity Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 25 Aug 2026 | Healthcare Equipment & Supplies | Market Cap: ₹673 Cr

Dentalkart aspires to double revenues every 3 to 4 years, aiming for significant growth in the long term. Management expects significant operating leverage leading to improved operating margins as revenue grows (Page 21).

From Vasa Denticity Ltd's Q4 FY26 earnings-call transcript · updated 25 Aug 2026.

Price

418

Market Cap

₹673 Cr

P/E Ratio

62.4

How does Vasa Denticity Ltd rank in Healthcare Equipment & Supplies?

Compare Vasa Denticity Ltd against every Healthcare Equipment & Supplies company this quarter on revenue, margins and earnings-call signals.

View Healthcare Equipment & Supplies leaderboard →

Vasa Denticity Ltd — Quarterly revenue & net profit

Revenue Net Profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹72 Cr, net profit ₹1 Cr.

Full financials →

📊 Revenue & Sales Performance

  • Dentalkart aspires to double revenues every 3 to 4 years, aiming for significant growth in the long term.
  • There is a large untapped "wallet share" within the current customer base, with potential for up to 10x growth in some states.
  • Focus on improving core areas—better customer service, faster delivery in key regions, and expanding assortments to include more categories—will drive multi-fold growth.
  • Operating leverage is expected as revenue grows, with manpower and warehouse costs not increasing proportionally, improving profitability.
  • Plans to scale SKU count from 23,000 to 35,000 reflect expansion into unmet categories.
  • The company expects mid-teen EBITDA margins in 2-3 years alongside growth.
  • Long-term target: reaching a ₹1000 crore revenue milestone in about 5-6 years, with customized smaller warehouses for faster delivery planned.

📈 Profitability & Margins

  • Management expects significant operating leverage leading to improved operating margins as revenue grows (Page 21).
  • Operating margins are projected to move from current lower levels to mid-teen EBITDA margins in 3-4 years (Page 12, 21).
  • FY26 was impacted by one-off issues such as stockouts and forex costs, which management believes are operational and being corrected (Page 2, 8, 21).
  • Revenue growth target: doubling top-line every 3-4 years, implying around 20-30% CAGR, though no precise guidance given due to market uncertainties (Page 4, 21).
  • Growth to be driven by improving core business focus: better assortment, faster delivery in key markets, and superior customer service (Page 20).
  • Own brand availability improvements expected to restore gross margins closer to historical levels (Page 12).
  • Cash flow and profitability expected to improve with better inventory management and operating efficiencies (Page 8).

🏗️ Capital Expenditure Plans

  • Currently, no immediate plans for large capital investment or acquisition, as the company recently decided not to proceed with a planned acquisition after 9 months of integration efforts.
  • Plans to optimize existing warehouses rather than aggressively opening new ones now; considering smaller warehouses (dark stores of 500-1,000 sq ft) in smaller cities for faster delivery in the future.
  • Future investments may prioritize enhancing technology such as AI-driven recommendation and search engines, improving supply chain, and customer service systems.
  • Cash on the balance sheet is planned to be parked and used as growth capital over the years, with no immediate large-scale investment plans.
  • No funds planned to be raised currently; existing debt lines available if needed for future growth.
  • Potential capital allocation towards expanding SKU offerings (from 23,000 to 35,000) gradually, based on experimentation with new product categories.

💰 Fundraising & Capital Structure

  • Currently, there is no plan to raise funds through equity or debt.
  • The company has sufficient funds available for growth capital and future expansion.
  • If fundraising becomes necessary in the future, the preferred route would be raising debt.
  • The company has a debt line of ₹15 crore available from financial partners.
  • A stable rating facilitates easier access to debt whenever required.

📋 Order Book & Pipeline

The document does not explicitly provide specific details on the current or expected orderbook or pending orders in numerical terms. However, relevant insights include: - Dr. Vikas Agarwal mentions strong demand with people requesting products and bulk orders that they were sometimes unable to supply in the past. - Dentalkart still has a small wallet share in its customer base, indicating significant room for growth (up to 10x) in some states. - There is an emphasis on improving product availability, assortment, and faster delivery to meet demand better. - Past stockouts of own high-margin products occurred but are being addressed with supply chain improvements. - The company expects order growth and improved customer service to increase order volumes going forward. In summary, while exact orderbook numbers are not mentioned, the company sees strong underlying demand with plans to optimize inventory and delivery to capture more orders.

Key Metrics

Frequently Asked Questions

What were Vasa Denticity Ltd Q4 FY26 results?

Dentalkart aspires to double revenues every 3 to 4 years, aiming for significant growth in the long term. Management expects significant operating leverage leading to improved operating margins as revenue grows (Page 21).

What is Vasa Denticity Ltd share price analysis?

Vasa Denticity Ltd currently shows a neutral. The stock trades at a P/E of 62.4 with a market cap of ₹673 Cr. Investors should review the full earnings analysis for detailed insights.

Is Vasa Denticity Ltd planning capital expenditure?

Currently, no immediate plans for large capital investment or acquisition, as the company recently decided not to proceed with a planned acquisition after 9 months of integration efforts.

Keep Vasa Denticity Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

What Vasa Denticity Ltd's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

  • OSEL Devices Ltd (Q4 FY26)

    PAT growth was 45.7% in FY26; management is optimistic about sustaining or improving profitability and EPS in coming years. Key concall takeaways from OSEL…

  • QMS Medical (Q4 FY26)

    INR 13 crores in FY26 to INR 18-20 crores in FY27. Key concall takeaways from QMS Medical's Q4 FY26 earnings call — and how it ranks against sector peers.

  • Tarsons Products (Q4 FY26)

    Margins may face pressure short-term due to raw material price volatility but should stabilize around current levels (gross margin not below 65%). Key concall…

  • Poly Medicure (Q4 FY26)

    Management confident of 15-17% sustainable organic growth over next 3-5 years excluding acquisitions. Key concall takeaways from Poly Medicure Ltd's Q4 FY26…